Scipher Medicine Corporation

Berg LLC

Bpgbio, Inc.

The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.

Viatcheslav R Akmaev

Niven Rajin Narain

Nancy J Schoenbrunner

Keith J Johnson

Asher Ameli

Theodore R Mellors

Marc Santolini

Susan Dina Ghiassian

Rangaprasad Sarangarajan

Wenfang Sybil Wu

Shobha Ravipaty

Tracey Friss

Vijetha Vemulapalli

Shiv Srivastava

Vivek Kannoth Vishnudas

Albert Dobi

Michael Andrew Kiebish

Nikunj Narendra Tanna

Susan Ghiassian

Vivek K Vishnudas

Leonardo Rodrigues

Lixia Zhang

Jennifer Cullen

Eric Milliman

Methods for diagnosing the presence of BCR in prostate cancer in a subject are provided, such methods including the detection of levels of a variety of biomarkers diagnostic of BCR. Compositions in the form of kits and panels of reagents for detecting the biomarkers of the invention are also provided.

Markers for the diagnosis of biochemical recurrence in prostate cancer

Presented herein are systems and methods for developing classifiers useful for predicting response to particular treatments. For example, in some embodiments, the present disclosure provides a method of treating subjects suffering from an autoimmune disorder, the method comprising administering an alternative to anti-TNF therapy to subjects who have been determined to be non-responsive via a classifier established to distinguish between responsive and non-responsive prior subjects in a cohort who have received the anti-TNF therapy.

Methods of treating a subject suffering from rheumatoid arthritis with anti-TNF therapy based in part on a trained machine learning classifier

Presented herein are systems and methods for validating and/or developing (e.g., training) a classifier that identifies a subject suffering from an autoimmune disease (e.g., rheumatoid arthritis, RA) as likely responsive or likely non-responsive to a therapy (e.g., an anti-TNF therapy) prior to any administration of the therapy to the subject.

Assessing responsiveness to therapy

The present invention encompasses filamin A (FLNA) binding proteins. Specifically, the invention relates to antibodies to FLNA. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention in methods of diagnosis, monitoring and prognosis of prostate cancer are also provided.

Filamin A binding proteins and uses thereof

Methods of treating a subject suffering from rheumatoid arthritis with alternative to anti-TNF therapy based in part on a trained machine learning classifier

Systems, methods, and computer-readable medium are provided for healthcare analysis. Data corresponding to a plurality of patients is received. The data is parsed to generate normalized data for a plurality of variables, with normalized data generated for more than one variable for each patient. A causal relationship network model is generated relating the plurality of variables based on the generated normalized data using a Bayesian network algorithm. The causal relationship network model includes variables related to a plurality of medical conditions or medical drugs. In another aspect, a selection of a medical condition or drug is received. A sub-network is determined from a causal relationship network model. The sub-network includes one or more variables associated with the selected medical condition or drug. One or more predictors for the selected medical condition or drug are identified.

Bayesian causal relationship network models for healthcare diagnosis and treatment based on patient data

Presented herein are systems and methods for developing classifiers useful for predicting response to particular treatments. For example, in some embodiments, the present disclosure provides a method of treating subjects suffering from an autoimmune disorder, the method comprising a step of: administering an anti-TNF therapy to subjects who have been determined to be responsive via a classifier established to distinguish between responsive and non-responsive prior subjects in a cohort who have received the anti-TNF therapy.

Methods of treating a subject suffering from rheumatoid arthritis based in part on a trained machine learning classifier

Method of treating a subject suffering from rheumatoid arthritis with anti-TNF therapy based on a trained machine learning classifier

Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including the detection of levels of variety of biomarkers diagnostic of prostate cancer, including filamin A alone, or in combination with one or more additional biomarkers of prostate cancer, including, PSA, keratin 4, keratin 7, keratin 8, keratin 15, keratin 18, keratin 19, tubulin-beta 3, filamin B, and LY9. Additionally, age can be used as a predictor variable. The invention also provides methods of treating prostate cancer which rely on diagnostic information obtained based on the detection of biomarkers of prostate cancer, including filamin A alone, or in combination with one or more additional biomarkers of prostate cancer, including, PSA, keratin 4, keratin 7, keratin 8, keratin 15, keratin 18, keratin 19, tubulin-beta 3, filamin B, LY9, and/or age. Compositions in the form of kits and panels of reagents for detecting the biomarkers of the invention are also provided.

Use of markers including filamin A in the diagnosis and treatment of prostate cancer

Growing community of inventors

Sudbury, MA, United States of America

Viatcheslav R Akmaev